Kensington Investment Counsel LLC Has $1.81 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Kensington Investment Counsel LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 1.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 2,041 shares of the company’s stock after selling 20 shares during the period. Kensington Investment Counsel LLC’s holdings in Eli Lilly and Company were worth $1,808,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of LLY. Dorsey Wright & Associates raised its position in Eli Lilly and Company by 1.5% in the third quarter. Dorsey Wright & Associates now owns 18,733 shares of the company’s stock valued at $16,597,000 after purchasing an additional 271 shares during the last quarter. Dunhill Financial LLC increased its stake in shares of Eli Lilly and Company by 15.0% in the third quarter. Dunhill Financial LLC now owns 643 shares of the company’s stock valued at $570,000 after buying an additional 84 shares during the period. MCIA Inc raised its holdings in Eli Lilly and Company by 6.7% in the 3rd quarter. MCIA Inc now owns 254 shares of the company’s stock valued at $208,000 after buying an additional 16 shares during the last quarter. Main Management ETF Advisors LLC acquired a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $687,000. Finally, Orion Portfolio Solutions LLC grew its holdings in Eli Lilly and Company by 2.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 38,242 shares of the company’s stock worth $33,880,000 after acquiring an additional 816 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Bank of America cut their price objective on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Finally, Truist Financial increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,007.94.

Eli Lilly and Company Price Performance

LLY stock opened at $826.71 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company’s 50-day moving average is $842.70 and its 200-day moving average is $871.52. The stock has a market capitalization of $784.81 billion, a PE ratio of 89.37, a price-to-earnings-growth ratio of 3.14 and a beta of 0.41. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 EPS. Equities research analysts expect that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.